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Background: This study aimed to determine the clinical efficacy of various immune interventions on mother-to-child
transmission (MTCT) of hepatitis B virus (HBV).
Methods: We retrieved different immune strategies on how to prevent MTCT reported in the literature from Chinese
and English electronic databases from the viewpoint of intrauterine and extrauterine prevention. Relative risk (RR) and
95% confidence interval (CI) methods were used.
Results: Twenty-five articles on intrauterine prevention and 16 on extrauterine prevention were included in the
analysis. Intrauterine prevention could reduce infants’ HBV infection rate (RR = 0.36, 95% CI: 0.28-0.45) and increase their
anti-hepatitis B surface–positive rate (RR = 2.42, 95% CI: 1.46-4.01) at birth. Compared with passive immunization,
passive-active immunization could reduce infants’ HBV infection rate (RR = 0.66, 95% CI: 0.52-0.84) at birth, even at more
than 12 months of age (RR = 0.54, 95% CI: 0.42-0.69). Subgroup analysis demonstrated similar results except for
pregnant women who were hepatitis B surface antigen–positive. Funnel plots and Egger’s tests showed publication
bias mainly in intrauterine prevention not in extrauterine one.
Conclusions: The long-term protective effect of pregnant women injected with hepatitis B immunoglobulin during
pregnancy should be further validated by large-scale randomized trials. Newborns of pregnant women who carried
HBV should undergo a passive-active immunization strategy.
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Hepatitis B virus (HBV) infections are a global health
problem [1]. Studies have shown that in neonates born to
women who were hepatitis B surface antigen (HBsAg)-
positive, 10–20% were infected with HBV, whereas those
born to mothers who were HBsAg- and hepatitis B e
antigen (HBeAg)-positive (double positive, DP), 90%
were infected with HBV [2]. Mother-to-child transmis-
sion (MTCT) greatly contributes to the persistence of
the high number of HBV carriers because infections* Correspondence: liupeiseu@163.com
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unless otherwise stated.occurring in neonates and in childhood result in a chronic
HBV rate of 80–90% and 30–50%, respectively [3].
Since the introduction of HBV vaccines (HBVac), the
use of hepatitis B immunoglobulin (HBIG) and HBVac,
termed passive-active immunization, has been efficient
for preventing MTCT of HBV [4-6]. In the 1980s, studies
showed that in newborns of HBsAg-positive mothers, the
vertical transmission rate was reduced to 23% after vaccin-
ation with HBIG [7] and to 3–7% after passive-active
immunization [8]. Although a meta-analysis showed that
the passive-active immunization was effective [5], Kenneth
et al. [9] found that most of the studies were of low quality
(e.g., lacking blinding and allocation concealment); few
studies involved the effect of evaluating mothers who were
HBsAg-positive and HBeAg-negative (single positive, SP).
Furthermore, 10–20% of newborns with HBsAg-
positive mothers are still chronically infected with HBV,is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Jin et al. BMC Pediatrics  (2014) 14:307 Page 2 of 17even after being vaccinated with HBIG and HBVac
[10-12]. Wang et al. [13] and Zhang et al. [14] found that
most immunization failures in newborns with DP mothers
were due to intrauterine infection [11,15]. HBsAg does
not cross the placenta, whereas HBeAg can cross the pla-
centa and reach the fetus [15,16]. These studies suggested
that intrauterine HBV infection had a close relationship
with HBeAg-positive mothers, preterm birth, and HBV in
the placenta [11].
Several studies in China have suggested that there are
protective effects, namely lower HBV infection rates or
higher anti–hepatitis B surface (HBs) levels for newborns
after their mothers were injected with HBIG during
pregnancy [17-19] than those in a control group in-
cluded in some meta-analyses [20,21]. However, Yuan
et al. [22] found that there were no significant differ-
ences in newborns between vaccination and no vaccin-
ation with HBIG during pregnancy; they also suggested
that HBV intrauterine transmission was not common
[23-25]. Although previous meta-analysis to support the
protective effects for newborns after their mothers were
injected with HBIG during pregnancy, because they
ignored the randomization group, or an imbalance of
HBeAg infection status in pregnancy women could have
potentially biased the results. Moreover, there was ser-
ious heterogeneity in these studies because of the quality
of the studies included and the infection status of the
mothers [26].
Therefore, based on system review and previous meta-
analysis, this study aimed to update and again evaluate
the effects of different immunization interventions, in-
cluding mothers injected with HBIG during pregnancy
and newborns injected with HBVac and/or HBIG to
interrupt the MTCT of HBV.
Methods
Search strategy
We searched the Medline, EMBASE, Cochrane Library,
China Biological Medicine Database, Chinese National
Knowledge Infrastructure, and VIP Database for Chinese
Technical Periodicals databases between January 1980 and
December 2013 for relevant randomized controlled trials
(RCTs) written in English and Chinese peer-reviewed
literature. We used the terms “HBIG” (or “hepatitis B
immunoglobulin”) and “HBV” (or “hepatitis B virus”) and
“intrauterine” (or “ectopic” or “pregnant” or “pregnancy”
or “mother” or “children” or “infant” or “newborn”). The
bibliographies of the original studies, reviews, and relevant
conference abstracts were manually searched.
Inclusion and exclusion criteria
The inclusion criteria designs or epidemiologic methods
were RCTs. The subjects were HBsAg- and HBeAg-
positive pregnant women or HBsAg-positive pregnantwomen with a clear classification of HBeAg-positive and
HBeAg-negative. The experimental and control groups
were comparable, and one of the following comparisons
was made. (1) In the experimental group, women in the
third trimester of pregnancy were injected with HBIG;
newborns were injected with HBIG and HBVac. In the
control group, only newborns were injected with HBIG
and HBVac. (2) In the experimental group, newborns
were injected with HBIG and HBVac. In the control
group, only newborns were injected with HBVac. (3) In
the experimental group, women in the third trimester of
pregnancy were injected with HBIG; newborns were
injected with HBIG and HBVac. In the control group,
only newborns were injected with HBVac. Subjects were
asymptomatic HBsAg carriers during the study period.
Exclusion criteria were studies without a control group
and studies with a control group without randomization.
Only recent or detailed studies were chosen for repeated
published studies.
Data extraction and definitions of outcome
Two researchers (HJ and YYZ) independently selected
relevant studies and made a post-hoc assessment of
methodological quality by means of the Cochrane library
study quality evaluation tool [27]. The extracted data in-
cluded the first author’s name, year of publication, study
method, treatment protocol, sample size, duration of
follow-up, inclusion/exclusion criteria, and relevant
outcome data.
With regard to outcome, we estimated the rate of in-
fant HBV infection (HBsAg or HBV DNA) or protection
(HBsAb) at various time points (within 24 hours of
birth, at 7–12 months of age, and after 12 months of
age) as the primary outcome. HBV intrauterine infec-
tion was defined as HBsAg and/or HBV DNA positivity
in neonatal peripheral or umbilical blood within 24 hours
of birth and before administration of active or passive im-
mune prophylaxis. HBsAg-positive infections were classi-
fied as events (HBsAg-positive at any time >1 month of
age) or as chronic (HBsAg-positive for 6 months).
Quality assessment
The quality of the studies was evaluated using the
Cochrane Handbook for Systematic Reviews of Interven-
tions (Additional file 1: Table S1), version 5.1.0, recom-
mended standard: random sequence generation, allocation
concealment, blinding, incomplete outcome data, selective
reporting, and other biases. The risk of bias was regarded
high in the presence of high bias in any domain, low if all
key domains (except random sequence generation and
allocation concealment) were of low bias, and unclear in
all other cases. Two authors (HJ and ZT) independently
assessed the risk of bias; when necessary, consensus was
determined through help of a third author (PL).
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Statistical analysis was performed according to the
intention-to-treat principle. The estimated pooled rela-
tive risk (relative ratio, RR) and 95% confidence interval
(95% CI) were determined by the Mantel–Haenszel
fixed-effects model, or the inverse variance random-
effects model. The heterogeneity test was used with the
chi-squared test and I2. An I2 index of 25%, 50%, and
75% indicated a low, moderate, and high degree of het-
erogeneity, respectively. P < 0.10 in the chi-squared test
showed the existence of heterogeneity between studies.
Subgroup analysis included mothers with HBeAg
status, the length of follow-up, and the quality of the
included study. The Begg’s [28] and Egger’s [29] methods
were used to check for publication bias. For all tests, P ≤
0.05 or 95% CIs not including “1” indicated statistical
significance. The statistical analysis software used was
RevMan 5.1.0 (Copenhagen: Nordic Cochrane Centre,
The Cochrane Collaboration, 2011).
Results
Search results
Figure 1 is a flow chart of the included studies. The
number of RCT studies on intrauterine and extrauterine
prevention was 30 [22,30-58] and 24 [8,12,59-80], re-
spectively. Among studies on intrauterine prevention,
five were excluded because of duplicate publication and
the remaining 25 (eight on mothers who were DP, 17 on
those who were HBsAg- and/or HBeAg-positive), which
were conducted in the mainland of China, were in-
cluded. Among the studies on extrauterine prevention,Figure 1 Flow chart of included studies.eight studies were excluded because of duplicate publica-
tion, and the remaining 16 (13 on mothers who were
HBsAg- and HBeAg-positive, three on those who were
HBsAg- and/or HBeAg-positive) were included. The char-
acteristics of included studies are shown in Tables 1 and 2.
Quality assessment
In intrauterine prevention (Figure 2A and Additional
file 2: Figure S1A), four studies indicated that a random
table was applied [22,32,35,54], whereas the remainder
did not report the details of random-sequence gener-
ation. Allocation concealment was an undefined risk in
the included studies because it was not reported. Four
studies had a low attrition bias [22,32,36,51]; others were
unclear. Performance and detection biases were low.
Ten studies had high risk of reporting bias because of
selective reporting.
In extrauterine prevention (Figure 2B and Additional
file 2: Figure S1B), two studies indicated that a random
table was applied [64,68], whereas the remainder did not
report the details of random-sequence generation. All
allocation concealment was unclear. Four studies had a
low attrition bias [12,61,67,80]; others were unclear.
Performance and detection biases were low.
Meta-analysis results
Intrauterine and extrauterine prevention studies
Table 3 and Figure 3A show the comparison of
immunization effects on newborns of HBV-infected
women injected with HBIG and those without HBIG dur-
ing pregnancy; they also show all of the newborns were
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HBsAg+ HBsAb+ HBsAg+ HBsAb+ HBsAg+ HBsAb+
Ji 2003 [30] 21-31 1 T: HBIG 200 IU (7,8,9) NR T:29 T:3 T:10 NR NR NR NR
C: none C:31 C:5 C:3
Xu 2006 [31] NR 1 T: HBIG 200 IU (7,8,9) NR T:30 T:7 NR NR NR NR NR
Repeated [32] C: none C:30 C:20
Yuan 2006 [22] 20-33 1 T: HBIG 400 IU (7,8,9) T : HBIG 200 IU(0) + RV 5 ug(0,1,6) T:118 T:27 T:0 T:13 T:101 NR NR
C: Diluent C: HBIG 200 IU(0) + RV 5 ug(0,1,6) C:113 C:32 C:0 C:17 C:112
Chen 2007 [33] NR 1 T1: HBIG 200 IU (7,8,9) T1: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) T1:45 T1: 1 T1: 14 T1: 1 T1:33 NR NR
T2: None T2: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) T2:44 T2: No T2: No T2: 3 T2: 35
C:None C: RV 5ug(0,1,6) C:49 C:13 C: 4 C: 13 C: 32
Sun 2007 [34] NR 1 T1: HBIG 200 IU (7,8,9) T1: HBIG 200 IU(0,0.5) + V 5 ug(0,1,6) T1:77 T1: 2 NR T1:1 T1: 73 T1:0 T1: 54
T2:None T2: HBIG 200 IU(0,0.5) + V 5 ug(0,1,6) T2:76 T2: 10 T2: 4 T2: 70 T2:1 T2: 50
C: None C : V 5ug(0,1,6) C:70 C: 9 C: 8 C: 58 C: 4 C: 30
Wang 2007 [35] NR 1 T: HBIG 200 IU (4–9) T: HBIG 200 IU(0,0.5) + V 10 ug(1,2,7) T:32 T: 2 NR T: 2 NR NR NR
C: none C: HBIG 200 IU(0,0.5) + V 10 ug(1,2,7) C:31 C: 11 C: 12
Yan 2009 [36] 22-35 1 T: HBIG 400 IU (7,8,9) T: HBIG 200 IU(0,0.5) + RV 10 ug(0,1,6) T:106 T:10 T:37 T: 9 T: 82 T:8 T: 93
C: none C: RV 10ug(0,1,6) C:98 C:23 C: 9 C: 21 C: 46 C:20 C: 69
Cui 2011 [37] NR 1 T: HBIG 200 IU, 3 time T: HBIG 100 IU, 2time + RV 5 ug, 0, 1,6 T:106 NR NR NR NR T:5 T:96
C: none C: RV 5 ug, 0, 1,6 C:82 C:16 C:60
Zhu 1997 [38] NR 1 T: HBIG 200 IU (7,8,9) NR T:37 T: 6 NR NR NR NR NR
C:32 C: 12
Repeated [39] 2 C: none T:68 T: 0 NR NR NR NR NR
C:70 C: 3
Jia 2001 [40] NR 1 T: HBIG 200 IU (7,8,9) NR T:15 T: 1 NR NR NR NR NR
C:16 C: 7
2 C: none T:25 T: 0 NR NR NR NR NR
C:30 C: 3
Chi 2002 [41] NR 1 T: HBIG 200 IU (7,8,9) NR T:27 T:4 NR NR NR NR NR
C:29 C:10












Table 1 Characteristics of intrauterine and extrauterine prevention for newborns born to HBsAg- and/or
HBeAg-positive women (Continued)
Chen2003 [42] NR 1 T: HBIG 200 IU (7,8,9) NR T:18 T:2 NR NR NR NR NR
C:15 C:6
2 C: none T:26 T: 1 NR NR NR NR NR
C:20 C: 2
Han 2003 [43] NR 1 T: HBIG 200 IU (7,8,9) T: HBIG 200 IU(0,0.5) + V 5 ug(1,2,7) T:83 T:21 NR T: 5 NR NR NR
C:52 C:23 C: 7
Repeated [44] 2 C: None C : HBIG 200 IU(0,0.5) + V 5 ug(1,2,7) T:43 T: 3 NR T: 0 NR NR NR
C:38 C: 9 C: 5
Xing 2003 [45] 22-38 1 T: HBIG 200 IU (7,8,9) NR T:16 T: 2 NR NR NR NR NR
C:15 C: 6
Repeated [46] 2 C: None T:30 T: 0 NR NR NR NR NR
C:25 C: 3
Zhu 2003 [47] NR 1 T: HBIG 200-400 IU (7,8,9) T: HBIG 100 IU(0,0.5) + RV
5 ug(1,2,7) or PDV 30 ug(1,2,7)
T:169 T:21 NR NR NR NR NR
C:189 C:49
Repeated [48] 2 C: none C: HBIG 100 IU(0,0.5) + RV
5ug(1,2,7) or PDV 30 ug(1,2,7)
T:318 T:7 NR NR NR NR NR
C:304 C:22
Chen 2006 [49] NR 1 T: HBIG 200 IU (7,8,9) NR T:16 T: 4 NR NR NR NR NR
C:14 C: 9
2 C: none T:34 T: 1 NR NR NR NR NR
C:36 C: 5
Yang 2006 [50] NR 1 T: HBIG 200 IU (4–9) NR T:117 T: 12 T:7 NR NR NR NR
C: None C:90 C: 48 C: 0
2 T: HBIG 200 IU (7,8,9) T:46 T: 2 T:10 NR NR NR NR
C: None C:32 C:14 C: 0
Yu 2006 [51] NR 1 T1: HBIG 200-400 IU (7–10) NR T1:8 T1:3 NR NR NR NR NR
T2:7 T2:5
C:8 C: 8
2 T2: HBIG 200 IU (7,8,9) T1:18 T1:0 NR NR NR NR NR
T2:22 T2:0
C:20 C:2C: Diluent
Ji 2007 [52] NR 1 T: HBIG 200 IU (7,8,9) T: HBIG 200 IU(0) + RV 5 ug(0,1,6) T:30 T:2 NR T: 1 NR NR NR
C:26 C:10 C: 6











Table 1 Characteristics of intrauterine and extrauterine prevention for newborns born to HBsAg- and/or
HBeAg-positive women (Continued)
C:84 C:5 C: 3
Liu 2007 [53] NR 1 T: HBIG 200 IU (7,8,9) T: HBIG 200 IU(0,0.5) + RV 10 ug(0,1,6) T:12 T: 1 T: 4 T: 0 T:10 NR NR
C:9 C: 2 C: 1 C: 2 C: 4
2 C: None C: HBIG 200 IU(0,0.5) + RV 10 ug(0,1,6) T:31 T: 1 T: 12 T: 0 T:24 NR NR
C:34 C: 1 C: 12 C: 1 C:25
Wang 2008 [54] 20-33 1 T:HBIG 200 IU(5–9) T: HBIG 200 IU(0,0.5) + V T:79 T:8 NR T: 7 NR NR NR
C:60 C: 19 C: 14
2 C: None C:V T:80 T: 2 NR T: 0 NR NR NR
C:60 C:8 C: 5
Zhao 2008 [55] 20-34 1 T: HBIG 200 IU (7,8,9) NR T:37 T: 6 NR NR NR NR NR
C:32 C:12
2 C: none T:66 T: 0 NR NR NR NR NR
C:69 C:3
Liu 2009 [58] NR 1 T: HBIG 200 IU (7,8,9) NR NR NR NR NR NR NR NR
2 C: none T:100 T: 1 NR NR NR NR NR
C:120 C:4
Yuan 2009 [57] 20-40 1 T1: HBIG 200 IU (7,8,9) T1: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) T1:4 NR NR T1: 0 T1:13 NR NR
T2:9 T2: 3 T2: 7
T2: None T2: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) C:13 C: 5 C: 10
2 C: None C: RV 5 ug(0,1,6) T1:23 NR NR T1:1 T1:23 NR NR
T2:13 T2:2 T2:12
C:13 C: 1 C: 7
Li 2013 [58] 24-35 1 T: HBIG 200 IU (7,8,9) T: HBIG 100 IU, 6 h + RV 10 ug, 0, 1,6 T:38 T:2 T:34 T:0 T:36 NR NR
C:34 C:12 C:15 C:11 C:15
2 C: none C: HBIG 100 IU, 6 h + RV 10 ug, 0, 1,6 T:14 T:0 T:13 T:0 T:14 NR NR
C:28 C:3 C:20 C:1 C:25
1)E = HBeAg, 1 refers to pregnancy with HBeAg and HBsAg positivity; 2refers to pregnancy with HBsAg positivity and HBeAg negativity.
T, experimental group; C, control group.











Table 2 Characteristics of extrauterine prevention alone for newborns born to HBsAg- and/or HBeAg-positive women




Newborn 7-12month infant >12 month child
HBsAg-pos HBsAb-pos HBsAg-pos HBsAb-pos HBsAg-pos HBsAb-pos
Lo 1985 [59-61] 1 T: HBIG50 IU(0) + PDV5ug T:36 NR NR T:4 T:32 NR NR
(0.5,1.5,2.5); C: PDV5ug (0.5,1.5,2.5) C:38 C: 9 C:30
Sha 1985 [62] 1 T: HBIG 0.5 ml(0) + PDV 20ug (0,1,2,12); T:19 T:13 T:18 T:4 T :10 NR NR
C: PDV 20 ug(0,1,2,12) C:10 C:7 C:0 C:1 C:5
Wu 1986 [63] 1 T : HBIG 1 ml(0) + PDV 20ug (1,2,3) T:13; T:1; NR NR NR NR NR
C : PDV 20 ug(1,2,3) C:6 C:0
Farmer 1987 [64] 1 T: HBIG 0.25 ml (25 IU/kg)(0,1.5), T:21 NR NR T:3 T:17 NR NR
PDV5 ug(0,1.5, 6) C: PDV5 ug (0,1.5,6) C:18 C:4 C:13
Theppisai 1987 [65] 1 T: HBIG 200 IU(0) + PDV 10 ug (0,1,6) T:27 NR NR T:2 NR NR NR
C: PDV 10 ug(0,1,6) C:18 C:2
Ip1 989 [8,66,67] 1 T: PDV3 ug(0,1,2,6) + HBIG(0) T:64 NR NR T:8 NR T:9 T:47
C: PDV3 ug(0,1,2,6) C:64 C:15 C:15 C:52
Assateerawatt 1993 [68] 1 T:HBIG100IU(0) + RV20 ug (0,1,2,12) T:30 NR NR T:1 T:25 T:1 T:24
C: RV20 ug(0,1,2,12) C:30 C:2 C:22 C:3 C:21
Li 1994 [69] 1 T : HBIG 200 IU(0) + PDV (0,1,6) T1:20; C1:22 T1:7; C1: 7; T1:18;C1:3 T1:1; C1:3 T1:16; C1:19 NR NR
C : PDV (1,2,3). T2:20; C2:21 T2:7; C2: 8; T2:9; C2:2 T2:7; C2:7 T2:17; C2:11
PDV including 10 ug, 20 ug and 30 ug T3:22; C3:21 T3:7; C3: 7 T3:9; C3:2 T3:1; C3:2 T3:20; C3:20
Zhao 1994 [70] 1 T : HBIG 60 IU(0) + V 10 ug (0,1,6) T:40 T:2 T:35 T:2 T:36 NR NR
C : V 10 ug(0,1,6) C:26 C:5 C:9 C:7 C:15
Kang 1995 [71] 1 T: HBIG 200 IU(0,1) + RV1 10 ug (0,1,6) T:44 NR NR NR NR T: 0 T: 43
C: RV1 20 ug(0,1,6) C:41 C: 5 C: 35
Poovorawan 1997 [72-74] 1 T: HBIG 100 IU(0) + RV 10 ug (0,1,6,60) T:64 T:1 NR T: 0 T: 58 T:1 T:39
C: RV 10 ug(0,1,6,60) C:63 C:3 C:3 C: 54 C:3 C:35
Lin 2000 [75] 1 T : HBIG 50 IU(0) + RV 10 ug (0,1,6) T:31 T:4 T: 26 NR NR NR NR
C : RV 10 ug(0,1,6) C:39 C:2 C: 36
Meng 2001 [76] 1 T : HBIG 50 IU(0) + RV 10 ug (0,1,6) T:50 NR NR NR NR T:4 T:45
C : RV 10 ug(0,1,6) C:52 C:7 C:43
Wang 2000-2001 [77,78] 1 T: HBIG 100 IU(0,1) + RV 20 ug (1,2,7) T:104; C:241 T:20; C :76 NR T:21; C:81 NR T:26; C:96 NR











Table 2 Characteristics of extrauterine prevention alone for newborns born to HBsAg- and/or HBeAg-positive women (Continued)
Sehgal 1992 [79,80] 13) T: HBIG0.5 ml(0) + PDV10 ug(0,1,2) T:7; C:7 NR NR T:1; C:1 T:5;C:4 NR NR
2 C: PDV10 ug(0,1,2) T:17:C:14 NR NR T:1; C:1 T:13;C:13 NR NR
Xu 1995 [12] 1 T: HBIG 250 IU(0) + PDV 20 ug(0,1,6) T:11; C:31 NR NR T:1; C:10 NR T:1; C:10 NR
2 C: PDV 20 ug(0,1,6) T:17; C:29 NR NR T:0; C:2 NR T:1; C:2 NR
1)E = HBeAg, 1 refers to pregnancy with HBeAg and HBsAg positivity; 2refers to pregnancy with HBsAg positivity and HBeAg negativity. 2) Vaccination schedule is filled in () by the unit of month.
T, experimental group; C, control group.











Figure 2 Risk of bias graph of included studies about intrauterine and extrauterine prevention. A. Intrauterine prevention.
B. Extrauterine prevention.
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borns in the experimental group and 2082 in the control
group at birth were included in 23 RCTs (Table 3 and
Figure 3A). The meta-RR (95% CI) comparing these two
groups for newborn HBsAg infection rate was 0.36
(0.28, 0.45), and a medium level of heterogeneity was
observed (I2 = 41%). There were 530 infants in the ex-
perimental group and 506 in the control group who had
data on their serum HBsAg status at 7–12 months of
age that were included in eight RCTs, with a meta-RR
(95% CI) of 0.34 (0.22, 0.53) (I2 = 36%). However, only
one RCT included those at more than 12 months of age
(3 years), with a meta-RR (95% CI) of 0.33 (0.01, 7.59).
In subgroup analysis, there were similar protective
effects as in these results, whether for maternal HBeAg
status or for low risk and unclear bias (Table 3).Meta-analysis showed that newborns in the experimen-
tal group had a higher amount of protective antibodies at
birth, but not at the other time points (95% CI including
“1”), compared with the control group (Figure 3B). There
were 556 newborns in the experimental group and 538 in
the control group at birth, included in seven RCTs (Table 3
and Figure 3B). The meta-RR (95% CI) comparing these
two groups for newborn anti-HBs–positive rate at birth
was 2.42 (1.46, 4.01), and a medium level of heterogeneity
was observed (I2 = 64%). A total of 372 infants in the
experimental group and 380 infants in the control group
had data on their serum anti–HBs-positive status at 7–12
months of age were included in six RCTs, with a meta-RR
(95% CI) of 1.10 (0.99, 1.23) (I2 = 68%). However, only one
RCT included those who were older than 12 months of
age (3 years), with a meta-RR (95% CI) of 1.07 (0.86, 1.33).
Table 3 Comparison of immunization effects on intrauterine and extrauterine prevention in newborns of HBsAg- and/or
HBeAg-positive women1)
Pregnancy infection status Newborn infection status Detective time Number of included studies Sample size Meta-RR (95% CI)
Total (HBsAg+ and/or HBeAg+) HBsAg+ At birth 23 4274 0.36(0.28, 0.45)2)
7-12 month 8 1036 0.34(0.22, 0.53)2)
>12 month 1 153 0.33(0.01, 7.95)2)
HBsAb+ At birth 7 1094 2.42(1.46, 4.01)2)
7-12 month 6 757 1.12(1.00, 1.24)2)
>12 month 1 153 1.07(0.86, 1.33)2)
Subgroup (HBsAg+ and HBeAg+) HBsAg+ At birth 21 2159 0.40(0.32, 0.51)2)
7-12 month 8 812 0.37(0.23, 0.57)3)
>12 month 1 153 0.33(0.01, 7.95)2)
HBsAb+ At birth 7 909 3.05(2.19, 4.25)2)
7-12 month 6 614 1.15(0.99, 1.34)2)
>12 month 1 153 1.07(0.86, 1.33)2)
Subgroup (HBsAg+ and HBeAg-) HBsAg+ At birth 15 1892 0.22(0.14, 0.35)3)
7-12 month 4 224 0.22(0.06, 0.84)3)
HBsAb+ At birth 3 185 1.31(0.82, 2.10)3)
7-12 month 3 148 1.09(0.97, 1.22)3)
Subgroup (low+unclear bias) HBsAg+ At birth 12 1945 0.35(0.22,0.54)2)
7-12 month 5 643 0.52(0.30,0.91)3)
>12 month 1 153 0.33(0.01,7.95)3)
HBsAb+ At birth 6 980 3.02(1.48,6.15)2)
7-12 month 5 643 1.04(0.98,1.10)3)
>12 month 1 153 1.07(0.86,1.33)3)
Subgroup (high risk bias) HBsAg+ At birth 11 2329 0.37(0.29,0.47)3)
7-12 month 3 393 0.18(0.08,0.39)3)
HBsAb+ At birth 1 114 1.60(1.26,2.03)3)
7-12 month 1 114 1.49(1.23,1.81)2)
1)(Mother: HBIG/Infants: HBIG + vaccine) vs (Mother: none/Infants: HBIG + vaccine); 2)Random effects model, inverse variance method; 3)Fixed effects model,
Mantel-Haenszel method; values in boldface indicate statistical significance (P < 0.05).
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effects as these results between the experimental and
control groups, whether for maternal HBeAg status or for
low risk and unclear bias (Table 3).
All of the Begg’s tests, Egger’s tests, and funnel plots
revealed the existence of publication bias when compar-
ing two groups for newborn HBsAg infection rate at
birth and at 7–12 months of age (Figure 4A, B). Further-
more, the funnel plot was more skewed for the groups
with HBV infection rate than for those with an anti–
HBs-positive rate.
Extrauterine prevention studies
Table 4 and Figure 3C show the effects of immunization
between newborns injected with HBIG and HBVac and
those who were vaccinated with only HBVac and whose
mothers did receive HBIG injections during pregnancy.
There were 490 newborns in the experimental groupand 571 in the control group at birth in seven RCTs.
The meta-RR (95% CI) comparing these two groups for
newborn HBsAg infection rate was 0.66 (0.52, 0.84); a
low level of heterogeneity was observed (I2 = 28%). There
were 677 infants in the experimental group and 776 in
the control group with serum HBsAg status at 7–12
months of age that were included in 12 RCTs, with a
meta-RR (95% CI) of 0.54 (0.42, 0.69) (I2 = 0%). Seven
RCTs included data at more than 12 months of age, with
a meta-RR (95% CI) of 0.54 (0.42, 0.69). In subgroup
analysis, there were similar protective effects as these
results, whether for maternal HBeAg status or for low
risk and unclear bias (Table 4).
Meta-analysis showed that newborns in the experimen-
tal group had a higher amount of protective antibodies at
birth and at 7–12 months of age, but not at more than
12 months of age (95% CI including “1”), compared with
the control group (Figure 3D). There were 152 newborns
Figure 3 (See legend on next page.)
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Figure 3 Forest plot of HBV infection rates or the anti-HBs positive rate. (A) Forest plot of HBV infection rates of infants born to mothers
with HBsAg and/or HBeAg positive for intrauterine and extrauterine prevention (mother: HBIG/infants: HBIG + vaccine vs mother: none/infants:
HBUG + vaccine). (B) Forest plot of the anti-HBs positive rate of infants born to mothers with HBsAg and/or HBeAg positive for intrauterine and
extrauterine prevention (mother: HBIG/infants: HBIG + vaccine vs mother: none/infants: HBUG + vaccine). (C) Forest plots of the HBV infection rate
of infants born to mothers with HBsAg and/or HBeAg positive in extrauterine prevention. (D) Forest plot of the anti-HBs positive rate of infants
born to mothers with HBsAg and/or HBeAg positive in extrauterine prevention. (E) Forest plot of the HBV infection positive rate of infants born
to mothers with HBsAg and/or HBeAg positive for intrauterine and extrauterine prevention (mother: HBIG/infants: HBIG + vaccine vs mother:
none/infants: vaccine). (F) Forest plot of the anti-HBs rate of infants born to mothers with HBsAg and/or HBeAg positive for intrauterine and
extrauterine prevention (mother: HBIG/infants: HBIG + vaccine vs mother: none/infants: vaccine).
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at birth that were included in four RCTs (Table 4 and
Figure 3D). The meta-RR (95% CI) comparing these two
groups for newborn anti–HBs-positive rate at birth was
2.12 (1.66, 2.70); a higher level of heterogeneity was ob-
served (I2 = 95%). There were 296 infants in the experi-
mental group and 270 in the control group who hadFigure 4 Funnel plot of HBV infection rate or anti-HBs positive rate. (
HBsAg and/or HBeAg positive for intrauterine and extrauterine prevention.
with HBsAg and/or HBeAg positive for intrauterine and extrauterine preven
with HBsAg and/or HBeAg positive for intrauterine and/or extrauterine pre
mothers with HBsAg and/or HBeAg positive for intrauterine and/or extrautdata on their serum anti–HBs-positive status at 7–12
months of age that were included in eight RCTs, with a
meta-RR (95% CI) of 1.12 (1.03, 1.22) (I2 = 35%). Five
RCTs included data at more than 12 months of age,
with a meta-RR (95% CI) of 1.06 (0.96, 1.16). In sub-
group analysis, there were similar protective effects as
these results between the experimental and controlA) Funnel plot of HBV infection rate of infants born to mothers with
(B) Funnel plot of the anti-HBs–positive rate of infants born to mothers
tion. (C) Funnel plot of HBV infection rate of infants born to mothers
vention. (D) Funnel plot of the anti-HBs–positive rate of infants born to
erine prevention.
Table 4 Comparison of immunization effects on extrauterine prevention alone for newborns of HBsAg- and/or
HBeAg-positive women&
Pregnancy infection status Newborn infection status Detective time Number of included studies Sample size Meta-RR (95% CI)
Total (HBsAg+ and/or HBeAg+) HBsAg+ At birth 7 1061 0.66(0.52,0.84)3)
7-12 month 12 1451 0.54(0.42,0.69)3)
>12 month 7 1214 0.54(0.42,0.69)3)
HBsAb+ At birth 4 291 2.12(1.66,2.70)3)
7-12 month 8 566 1.12(1.03,1.22)3)
>12 month 5 502 1.06(0.96,1.16)3)
Subgroup (HBsAg+ and HBeAg+) HBsAg+ At birth 7 782 0.75(0.57,0.99)3)
7-12 month 12 1095 0.56(0.42,0.75)3)
>12 month 7 889 0.55(0.41,0.75)3)
HBsAb+ At birth 4 291 3.25(1.35,7.83)2)
7-12 month 9 443 1.14(1.05,1.24)3)
>12 month 5 502 1.06(0.96,1.16)3)
Subgroup (HBsAg+ and HBeAg-) HBsAg+ At birth 1 279 0.59(0.34,1.02)3)
7-12 month 3 356 0.64(0.39,1.06)3)
>12 month 2 325 0.63(0.41,0.97)3)
Subgroup (low + unclear bias) HBsAg+ At birth 4 348 0.82(0.58,1.18)3)
7-12 month 10 739 0.56(0.38,0.82)3)
>12 month 4 400 0.43(0.23,0.82)3)
HBsAb+ At birth 3 221 4.21(2.70,6.57)3)
7-12 month 8 566 1.12(1.03,1.22)3)
>12 month 4 400 1.05(0.93,1.17)3)
Subgroup (high risk bias) HBsAg+ At birth 3 713 0.58(0.42,0.81)3)
7-12 month 2 712 0.53(0.39,0.72)3)
>12 month 3 814 0.56(0.43,0.73)3)
HBsAb+ At birth 1 70 0.91(0.76,1.09)
7-12 month - - -
>12 month 1 102 1.09(0.93,1.27)
&(Mother: none/Infants: HBIG + vaccine) vs (Mother: none/Infants: vaccine); 2)Random effects model, inverse variance method; 3)Fixed effects model, Mantel-Haenszel
method; values in boldface indicate statistical significance (P < 0.05).
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ies with low risk and unclear bias (Table 4). However,
there was lack of data about anti–HBs-positive status
when comparing these two groups for newborns of
women with SP.
Egger’s test revealed the existence of publication bias
when comparing two groups for newborn HBsAg infec-
tion rate at more than 12 months of age and for newborn
anti–HBs-positive rate at birth (Figure 4C,D). The funnel
plots show similar results but with a more skewed shape.
Other prevention studies
Figure 3E and Figure 3F show a comparison of the
effects of immunization between HBV-infected mothers
who received HBIG during pregnancy and newborns
that received HBIG and HBVac versus newborns that
received HBVac. Meta-analysis showed that newborns inthe experimental group had a lower infection rate and a
higher amount of protective antibodies at each time
point than did the control group. Publication bias was
not shown because of the low number of included
studies.
Safety analysis
No adverse events—such as fever, rigor, skin rash, in-
flammation, scleroma at the locally injected area, impair-
ment of renal function, or other discomforts—were
found in any of the included studies.
Discussion
In this study, meta-analysis was used to investigate the
clinical effects of different immunization strategies on
interrupting MTCT of HBV. The main findings of our
study follow.
Jin et al. BMC Pediatrics  (2014) 14:307 Page 14 of 17First, our study found that multiple small doses of
intramuscular HBIG injection in HBV-carrying mothers
during the third trimester of pregnancy could reduce
infants’ HBV infection rate and increase their anti–HBs-
positive rate at birth. However, there was no statistical
significance in the anti–HBs-positive rate of newborns at
more than 7 months of age between the experimental
and control groups. Subgroup analysis, such as for DP
pregnant women and for the studies without a high risk
of bias, showed similar results. The possible mechanism
for this is that HBIG administration produces short-
term effects, whereas passive HBVac immunization has
long-term effects. Furthermore, only one RCT [34] with
3 years’ follow-up supported this view; its meta-RR (95%
CI) was 0.33 (0.01, 7.59). Recently, other studies [17,19]
have indicated that prenatal HBIG vaccination is effect-
ive and improves the immune response for DP pregnant
women. Shi et al. [20] and Xu et al. [21] used meta-
analyses to show the same viewpoint as these other stud-
ies, but Yuan et al. [22] proposed the opposite view.
They found that there were no significant differences in
newborns between those vaccinated and not vaccinated
with HBIG during pregnancy. Our study suggested that
multiple small doses of intramuscular HBIG injection
during the third trimester of pregnancy still need to be
proven by RCTs; this was based on the following consid-
erations. Most of the included studies had an unclear or
higher risk of bias and there was clearly publication bias.
Extensive HBIG vaccination might lead to immune re-
sistance to HBV strains, which potentially results in the
HBVac being ineffective. Additionally, it is possible to
produce antigen–antibody immune complexes in vivo in
pregnant women injected with HBIG that threaten ma-
ternal and fetal health.
Second, in pregnant women who carry HBV, passive-
active immunization can be efficient for preventing
MTCT of HBV [5], especially for DP pregnant women.
Notably, most of the RCT studies were carried out before
2000 because immunization strategies were recommended
by many countries at that same time. Additionally, many
included studies were of low quality, such as a lack of
blinding and allocation concealment. Fortunately, sub-
group analysis and funnel plots supported the previously
mentioned conclusion. There are few studies on SP preg-
nant women in the study because some quasi-RCT studies
without random allocation or with allocation according to
willingness were excluded. In SP pregnant women, sub-
group analysis showed a lower HBsAg infection rate for
newborns who received HBIG and HBVac than those who
had just HBVac at more than 12 months of age. This
suggests that newborns of SP pregnant women should
receive passive-active immunization [81].
Third, more attention should be paid to some neglected
issues in the application of clinical trials in vertical MTCTof HBV. Considering the feasibility of trials, many re-
searchers used the method of allocation according to pa-
tient willingness [82], not random allocation. Whether
pregnant women are willing to be injected with HBIG is
dependent on factors such as economic condition, edu-
cational level, and HBeAg status. Imbalance of these
factors between groups would bias the results. Further-
more, most—except for a few [22,31,54]—of the in-
cluded studies in our meta-analysis did not describe
how to randomly divide study subjects into groups. In
addition, blinding and control choice need to be care-
fully considered; therefore, researchers should increase
their cooperation with statisticians and epidemiologists
and carefully design clinical trials with them under the
guide of the CONSORT criteria before starting a trial.
Our study had the following advantages. (1) Multiple
immunization strategies were used to comprehensively
investigate, evaluate, and compare strategies. These
methods were helpful for minimizing the effect of bias
and for improving the accuracy of the study. (2) HBeAg
positivity had a close relationship with HBV DNA level.
Having access to HBeAg infection status was helpful for
controlling bias for evaluating immunization strategy
[81]. Wen et al. [83] found that offspring of HBeAg-
positive mothers were more likely to be infected and to
become chronic carriers than those of HBeAg-negative
mothers. This was most likely attributable to the differ-
ence in maternal viral load or HBV DNA level. (3) Un-
like previous meta-analyses [20,21], the quality of our
studies was evaluated using the Cochrane Handbook for
Systematic Reviews of Interventions, version 5.1.0, rec-
ommended standard. Subgroup analysis of non–high-
risk bias facilitated improved appraisal of evidence and
led to better health care. In addition, including more
studies increased the statistical efficacy.
Our study had the following limitations. (1) Different
from extrauterine prevention, intrauterine prevention
included these RCTs all from Chinese studies. This
limits our results in terms of how to generalize them to
other countries. (2) The meta-analysis of SP pregnant
women was based on subgroup analysis or non-RCT
studies; therefore, these results need to be verified by
further RCT studies. (3) Long-term effects in the RCTs
were difficult to obtain, especially for certain time
points. (4) A lack of sufficient information can bias the
results (e.g., mode of delivery, maternal HBV change, la-
boratory technology, patient HBV DNA level). If umbil-
ical blood is contaminated by maternal body fluids, the
error diagnosis of newborn HBV infection could misin-
form the final results. In addition, it is essential to con-
sider cost-effectiveness analysis, such as the relationship
between the cost of multiple small doses of HBIG and
protective effects, to evaluate different immunization
interventions.
Jin et al. BMC Pediatrics  (2014) 14:307 Page 15 of 17Conclusions
Although our meta-analysis shows a protective effect of
HBIG vaccination of women during the third trimester
of pregnancy, this should be further validated by long-
term, large-scale randomized trials. In addition, new-
borns of both DP women and SP women should receive
passive-active immunization.
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